Schneider and colleagues measured an IVA concentration of 0.15 ± 0.05 μg/mL in the sputum of a CF patient at 2.5 h post-IVA administration (29), which would have excluded antimicrobial activities of CFTR modulators in CF patients. This evidence concerns the gene CFTR and cystic fibrosis.